BioSpace News Archive

Drug Development

Sensei Biotherapeutics Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating SNS-101

Sensei Biotherapeutics, Inc. today announced a clinical supply agreement with Regeneron for its anti-PD1 therapy Libtayo ® (cemiplimab).

January 5, 2023
·
5 min read
Drug Development

InflaRx Provides Update on Planned Phase III Study Design in Pyoderma Gangrenosum with Vilobelimab and Status of its EUA Application in Critically Ill COVID-19 Patients

InflaRx N.V. today announced details related to the design of its planned Phase III study with vilobelimab in ulcerative PG, a rare neutrophilic and inflammatory skin disease with destructive, painful cutaneous ulcers.

January 5, 2023
·
8 min read
BioForest

Cardiac Dimensions Raises $35 Million in Series D Financing

Cardiac Dimensions ®, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced it has closed a $35 million Series D financing round.

January 5, 2023
·
5 min read
Business

Reset Pharmaceuticals Appoints Innes Meldrum as President and Chief Executive Officer

Reset Pharmaceuticals, Inc., a privately held biotechnology company focused on the development of innovative treatments to address mental health indications related to life-altering diseases, announces that Innes Meldrum has been appointed President and Chief Executive Officer.

January 5, 2023
·
4 min read
BioMidwest

Cogent Biosciences Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference

Cogent Biosciences, Inc. announced that Andrew Robbins, President and Chief Executive Officer will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 12, 2023 at 7:30 a.m. PT/10:30 a.m. ET.

January 5, 2023
·
1 min read
Genetown

ORYZON to Give Updates on Corporate Progress in January 2023

Oryzon Genomics, S.A. announced that its management will give an update on corporate progress at several international events in January.

January 5, 2023
·
7 min read
Pharm Country

Cabaletta Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference

Cabaletta Bio, Inc. announced that Steven Nichtberger, M.D., Chief Executive Officer, will present at the 41st Annual J.P. Morgan Conference being held in San Francisco, CA on Thursday, January 12th at 7:30 a.m. PT.

January 5, 2023
·
1 min read
Lone Star Bio

Salarius Pharmaceuticals Announces Issuance of New U.S. Patent for Next-Generation Targeted Protein Degraders

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) announces that on December 27, 2022 the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,535,603, titled “Deuterium-enriched Piperidinonyl-oxoisoindolinyl Acetamides and Methods of Treating Medical Disorders Using Same.”

January 5, 2023
·
6 min read
MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability

MorphoSys AG reported preliminary Monjuvi ® U.S. net product sales for the full year of 2022 and provided its financial guidance for 2023.

January 5, 2023
·
7 min read
Pharm Country

NRx Pharmaceuticals to Present Scientific Update at the 6th Annual Sachs Associates Neuroscience Innovation Forum in Conjunction with the 2023 J.P. Morgan Healthcare Conference

NRx Pharmaceuticals, Inc. announced that it will be presenting a scientific update of its Phase 2 and Phase 3 development program for NRX-101 in the treatment of suicidal bipolar depression at the upcoming 6th Annual Neuroscience Innovation Forum by Sachs Associates.

January 5, 2023
·
3 min read